doi: 10.22059/jsb.2021.308706.1424 49
Unlike earlier-generation weight-management agents, retatrutide is a triple receptor agonist , meaning it simultaneously activates three distinct hormonal receptors: GLP-1 (glucagon-like peptide-1) receptor promotes insulin secretion, reduces appetite, and slows gastric emptying [9] [10] GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin release and may improve fat metabolism [12] [13] Glucagon receptor increases energy expenditure and may reduce hepatic steatosis, as suggested by imaging data (MRI-PDFF) from Phase 2 trials, though this effect requires confirmation in larger studies [2] [5] This triple-agonist mechanism distinguishes retatrutide from agents such as semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), and is thought to produce more pronounced reductions in body weight and improvements in metabolic parameters
This meta-analysis explored one in particular, that has a serious impact: Coenzyme Q10 (CoQ10) It analyzed 12 clinical trials involving 362 patients with hypertension
Here, we show that uridine levels in the plasma and ovaries of aged mice are significantly reduced compared with young controls
Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N
